This proposal will test the hypothesis that the cell entry and cell penetration features of a novel recombinant protein derived from the adenovirus (Ad) capsid mediates non-viral delivery of a novel toxic corrole compound specifically to breast cancer cells for targeted breast cancer therapy. We will test this new therapeutic for targeting HER2+ breast cancer, which is characterized by aggressive tumor formation, metastasis, chemoresistance, a poor prognosis, high mortality, and amplification of the human epidermal growth factor receptor HER2 subunit. About 30% of breast cancers are HER2+, comprising a significant subset of breast cancers requiring novel alternatives to standard treatment. The targeting aspect of this conjugate will direct therapy specifically to HER2+ cells, thus avoiding normal cells and other dividing cells such as blood cells, hair cells, and gastrointestinal epithelium.
The Specific Aims of this project are to test the hypotheses that: ? 1) HerPBK10 targets corroles to HER2+ cells in vitro. Standard metabolic assays for measuring cell survival and proliferation will be used to determine the cytotoxicity of conjugates on a panel of HER2+ and HER2- cells in vitro, and to assess the effect of serum on conjugate activity, and determine optimal dosage. Spectrophotometric absorbance assays will be used to assess the assembly parameters of the conjugates under different storage times and temperatures. Flow cytometry, fluorescence microscopy, and cytotoxicity assays will be used to assess targeting specificity by competitive inhibition with a free ligand, delivery to HER2+ cells in a mixed cell culture, and delivery to isogenic cell lines expressing different levels of receptor subunits. Finally, apoptosis as a mechanism of cell death will be examined. 2) HerPBK10 targets corroles to HER2+ cells in vivo. A mouse xenograft tumor model of HER2+ breast cancer will be used to assess the therapeutic efficacy of conjugate delivery by both intratumoral injection and systemic delivery, and the presence of circulating heregulin will be assessed. The biodistribution and pharmacokinetics of conjugates will also be examined by harvesting and immunohistological processing of tissues, and collection of serum, after in vivo circulation. We will use ELISA-based assays to examine cytokine induction in both tumor model and immune competent mice and to examine induction of neutralizing antibodies in immune competent mice. Apoptosis as a mechanism of cell death in vivo will also be examined. This research is relevant to public health because the proposed project will develop a novel therapeutic that can specifically target HER2+ breast cancer. This targeted therapy should be improved over conventional treatment methods because normal cells should not be affected. As HER2+ breast cancer does not respond well to conventional ? therapies, this alternative therapy could provide a significant contribution to breast cancer treatment. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21CA116014-02
Application #
7394404
Study Section
Special Emphasis Panel (ZRG1-ONC-B (03))
Program Officer
Fu, Yali
Project Start
2007-04-10
Project End
2010-03-31
Budget Start
2008-04-04
Budget End
2010-03-31
Support Year
2
Fiscal Year
2008
Total Cost
$190,800
Indirect Cost
Name
Cedars-Sinai Medical Center
Department
Type
DUNS #
075307785
City
Los Angeles
State
CA
Country
United States
Zip Code
90048
Medina-Kauwe, Lali K (2013) Development of adenovirus capsid proteins for targeted therapeutic delivery. Ther Deliv 4:267-77
Hwang, Jae Youn; Lee, Jungwoo; Lee, Changyang et al. (2012) Fluorescence response of human HER2+ cancer- and MCF-12F normal cells to 200MHz ultrasound microbeam stimulation: a preliminary study of membrane permeability variation. Ultrasonics 52:803-8
Hwang, Jae Youn; Lubow, David J; Sims, Jessica D et al. (2012) Investigating photoexcitation-induced mitochondrial damage by chemotherapeutic corroles using multimode optical imaging. J Biomed Opt 17:015003
Hwang, Jae Youn; Park, Jinhyoung; Kang, Bong Jin et al. (2012) Multimodality imaging in vivo for preclinical assessment of tumor-targeted doxorubicin nanoparticles. PLoS One 7:e34463
Agadjanian, Hasmik; Chu, David; Hwang, Jae Youn et al. (2012) Chemotherapy targeting by DNA capture in viral protein particles. Nanomedicine (Lond) 7:335-52
Hwang, Jae Youn; Lubow, Jay; Chu, David et al. (2011) A mechanistic study of tumor-targeted corrole toxicity. Mol Pharm 8:2233-43
Hwang, Jae Youn; Gross, Zeev; Gray, Harry B et al. (2011) Multimode Optical Imaging for Translational Chemotherapy: In Vivo Tumor Detection and Delineation by Targeted Gallium Corroles. Proc SPIE Int Soc Opt Eng 7902:
Hwang, Jae Youn; Lubow, Jay; Chu, David et al. (2011) Investigating the photosensitizer-potential of targeted gallium corrole using multimode optical imaging. Proc SPIE Int Soc Opt Eng 7886:
Agadjanian, Hasmik; Ma, Jun; Rentsendorj, Altan et al. (2009) Tumor detection and elimination by a targeted gallium corrole. Proc Natl Acad Sci U S A 106:6105-10
Medina-Kauwe, L K (2007) ""Alternative"" endocytic mechanisms exploited by pathogens: new avenues for therapeutic delivery? Adv Drug Deliv Rev 59:798-809